Neurodegenerative Diseases Overview

Principles

Definition

Neurodegenerative diseases is an academic concept and research field dedicated to the study of a heterogeneous group of disorders characterized by the progressive degeneration and death of neurons, primarily within the central or peripheral nervous system. This field investigates the etiologies, cellular and molecular mechanisms, pathological processes, and clinical manifestations of these conditions, such as Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis, aiming to develop diagnostics, therapeutics, and preventative strategies for these debilitating illnesses.

Ontological type

Therapeutic Strategies

Molecular Pathology

Etiological Mechanisms

Key developments

Key Figures

Morphology-to-Molecular Shift era

Colin L. Masters[1], a prominent figure during the Morphology-to-Molecular Shift (1957–1986), held appointments at Harvard University[2] and the Albert Einstein College of Medicine[3]. Masters[1] catalyzed a decisive advance by identifying the amyloid plaque core protein in Alzheimer disease and Down syndrome, as detailed in the 1985 paper Amyloid plaque core protein in Alzheimer disease and Down syndrome[4]. This molecular anchoring work, illustrated by Masters[1] and the 1985 paper[4], began to shift neuropathology toward biochemical identities, enabling cross-population epidemiology and tissue-based studies that highlighted amyloid and cytoskeletal proteins as key substrates. Thus Masters[1]'s molecular approach established substrates and assays that enabled subsequent mechanistic research into neurodegenerative pathology involving amyloid[4] and cytoskeletal proteins.

Genetic Proteopathy Paradigm era

Heiko Braak [1] is a key figure in the Genetic Proteopathy Paradigm era, with affiliations including the University of Pennsylvania [3] and Jacksonville College [4]. His 2002 paper 'Staging of brain pathology related to sporadic Parkinson’s disease' [7] advanced the view that progressive protein misfolding and aggregation underlie neurodegeneration, shaping research toward staging, biomarkers, and therapies targeting protein aggregates in this era. Rudolph E. Tanzi [2] contributed to this era by identifying Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis [8], with affiliations to Rockefeller University [5] and Harvard University [6]. These findings highlighted the role of protein misfolding and gene dosage in neurodegenerative disease and helped anchor this era’s shift toward genetic-proteopathy models and cellular determinants of aggregation.

Biomarker-Led Precision Era era

Marco Colonna[1] is a prominent immunologist active in the Biomarker-Led Precision Era, with affiliations at Washington University in St. Louis[3] and the University of Toronto[4]. His key contribution, highlighted in the 2017 paper A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease[7], identifies a distinctive microglial state that restricts Alzheimer’s disease development, illustrating how microglial heterogeneity can serve as a biomarker-aligned mechanism for early diagnosis and mechanism-directed intervention. Michal Schwartz[2] has been affiliated with Massachusetts Institute of Technology[5] and the Weizmann Institute of Science[6] during the Biomarker-Led Precision Era. Schwartz[2] helped reveal how microglial states influence neuroimmune responses in Alzheimer’s disease, as illustrated by the 2017 paper A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease[7], underscoring biomarker-driven strategies for early diagnosis and mechanism-informed interventions in this era.